Projects per year
Abstract
Tuberculosis remains the most common cause of death due to a single infective organism. Despite the availability of a vaccine and chemotherapeutic options, the global disease burden remains relatively unaffected. The ability of the mycobacterial etiological agents to adopt a semidormant, phenotypically drug-resistant state requires that chemotherapy is both complex and lengthy. The emergence of drug resistance has raised the possibility of virtually untreatable tuberculosis. Furthermore, the currently used bacillus Calmette-Guerin vaccine has had mixed success in protecting susceptible populations. Given this backdrop, the need for novel anti-infectives and more effective vaccines is clearly evident. Recent progress, described herein, has seen the development and entry into clinical trials of several new drugs and vaccine candidates.
Original language | English |
---|---|
Pages (from-to) | 481-497 |
Number of pages | 17 |
Journal | Expert Review of Vaccines |
Volume | 7 |
Issue number | 4 |
DOIs | |
Publication status | Published - 1 Jan 2008 |
Keywords
- tuberculosis
- azole
- Mycobacterium
- diarylquinone
- isoxyl
- siderophore
Fingerprint
Dive into the research topics of 'New drugs and vaccines for drug-resistant Mycobacterium tuberculosis infections'. Together they form a unique fingerprint.Projects
- 2 Finished
-
Probing Novel Modes of Molecular Recognition by the Leukocyte Immunoglobulin-Like Receptor Family
Willcox, B. (Principal Investigator), Martin, A. (Co-Investigator) & Moss, P. (Co-Investigator)
Biotechnology & Biological Sciences Research Council
5/07/07 → 4/01/11
Project: Research Councils
-
A Biophysical Approach Towards Exploiting the Clinical Potential of Alloreactive T-Cell Recognition
Young, L. (Principal Investigator)
3/03/03 → 28/02/07
Project: Research Councils